Status:
RECRUITING
Predicting Breast Cancer With the BRAVE System
Lead Sponsor:
Université de Sherbrooke
Collaborating Sponsors:
Cancer Research Society
Conditions:
Breast Mass
Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
Breast cancer predominates among cancer diagnoses in Canadian women. It accounts for around 25% of new cases and contributes to 13% of all cancer-related deaths. In 2020, almost 27,400 Canadian women ...
Detailed Description
This study has two objectives, which will be studied in two separate groups. 1. To measure the sensitivity and specificity of BRAVE in identifying malignant lesions in a cohort of 300 women. 2. To as...
Eligibility Criteria
Inclusion
- ≥18 years old
- Able and willing to provide signed informed consent in French or English
- Recent mammogram (\< 6 months)
- Breast mass newly identified by palpation, mammography, sonography, or MRI and have been referred for additional imaging or evaluation.
- Specific inclusion Criteria:
- Group 1 - Normal Mammographic Breast Density (NMBD): Breast density A or B Group 2 - Elevated Mammographic Breast Density (EMBD): Breast density C or D
Exclusion
- Pregnant or breast-feeding women
- Breast implants or prior surgery/biopsy to breasts
- Any disease or condition limiting the capacity to complete the examination process
- Any previous or prescribed treatment against cancer
Key Trial Info
Start Date :
January 28 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06498388
Start Date
January 28 2025
End Date
December 31 2026
Last Update
February 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CIUSSS de l'Estrie - CHUS
Sherbrooke, Quebec, Canada, J1H5N4